<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211112053042N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-09-29</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>The effect of dural epidural puncture technique in comparison with combined epidural-spinal and epidural techniques in painless delivery and the consequences of labor, mother and newborn</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of dural epidural puncture technique in comparison with combined epidural-spinal and epidural techniques in painless delivery and the consequences of labor, mother and newborn</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66069</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Study subjects will be divided into three groups, epidural , dural epidural puncture and combined epidural-spinal , using a simple randomization method and using a table of random numbers. First, each person is assigned a number. Then, using the table of random numbers, each selected number is randomly assigned to one of the groups, and this work continues until the number of people in each group is completed. Therefore, the researcher will not have the authority to change the status of the assignment of people or to predict it. Randomization concealment will be done by a third person who does not participate in other stages of the intervention.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Painless delivery.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: Dural epidural puncture group: With the needle-through-needle technique, a Whitacre 25 gage spinal needle is used to confirm dural puncture in the axis of the epidural needle. 8-12 ml of ropivacaine 0.1% is used. Intervention 2: The second intervention group: Epidural anesthesia is performed like the epidural group and spinal anesthesia using Quincke 25 gage needle. 8-12 ml of ropivacaine 0.1% is used. Intervention 3: Control group: Epidural group: The pregnant woman is placed in a sitting position, then in the L2-L3 or L3-L4 regions with a midline approach, with a 17 gage epidural needle the epidural space is determined using loss of resistance to saline. 8-12 ml of ropivacaine 0.1% is used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after unidentified individuals.

When:
Access period starts 6 months after the results are published.

To whom:
Research centers and faculty members

Conditions:
At the request of the researcher and faculty members

Where to obtain:
Send email to the scientific respondent

How to obtain:
Within two months from the time of requesting and sending the email, the documents will be sent to the mentioned people

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hossein Delshad MD.</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Arghavan Gharbi, 45 meters from Golshahr Street, Karaj, Alborz Province</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3198683639</zip>
        <telephone>+98 26 3350 2347</telephone>
        <email>m.delshad@abzums.ac.ir</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hossein Delshad MD.</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Arghavan Gharbi, 45 meters from Golshahr Street, Karaj, Alborz Province</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3198683639</zip>
        <telephone>+98 26 3350 2347</telephone>
        <email>m.delshad@abzums.ac.ir</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women with ASA Class I, II
Gestation age 38-42weeks
Singleton
Vertex presentation
Entering the active phase of labor with dilatation less than 5 cm
A candidate for painless delivery
Pregnant women with consent to participate in the project</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Pregnant women with lack of consent to participate in the project
History of back surgery
Diseases related to pregnancy such as gestational hypertension, preeclampsia, gestational diabetes
Contraindications for performing neuraxial analgesia techniques
Known fetal anomaly
A condition with an increased risk of cesarean section, such as a history of previous cesarean section, a history of uterine rupture
Diseases of the central nervous system
Allergy to the drugs used in the study
Coagulation disorders, decreased platelet count
Local or systemic infection
The presence of blood or cerebrospinal fluid in the epidural catheter during the procedure
History of drug abuse
People who are unable to maintain the position when the needle is inserted
History of spine surgery
Presence of wound and infection at the needle entry site</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O80</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Encounter for full-term uncomplicated delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: Dural epidural puncture group: With the needle-through-needle technique, a Whitacre 25 gage spinal needle is used to confirm dural puncture in the axis of the epidural needle. 8-12 ml of ropivacaine 0.1% is used.</i_keyword>
      <i_keyword>The second intervention group: Epidural anesthesia is performed like the epidural group and spinal anesthesia using Quincke 25 gage needle. 8-12 ml of ropivacaine 0.1% is used.</i_keyword>
      <i_keyword>Control group: Epidural group: The pregnant woman is placed in a sitting position, then in the L2-L3 or L3-L4 regions with a midline approach, with a 17 gage epidural needle the epidural space is determined using loss of resistance to saline. 8-12 ml of ropivacaine 0.1% is used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Before the start of the procedure, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240 minutes after the procedure, cervical dilatation 6 cm, cervical dilatation 10 cm, immediately after the exit of the fetus. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Analgesia onset time. Timepoint: When with the first bolus injection, the pain score is &lt;= 3 based on VAS. Method of measurement: Ask the patient.</sec_outcome>
      <sec_outcome>Movement block. Timepoint: every 15 minutes. Method of measurement: Based on scoring Bromage criteria.</sec_outcome>
      <sec_outcome>Sensory block. Timepoint: every 15 minutes. Method of measurement: Sensory block at S2 and T10 levels.</sec_outcome>
      <sec_outcome>Systolic blood pressure. Timepoint: Before the procedure, 5, 10, 15, 30, 45, 60, 75, 105, 135, 165 minutes later. Method of measurement: Measurement with pressure gauge.</sec_outcome>
      <sec_outcome>Diastolic blood pressure. Timepoint: Before the procedure, 5, 10, 15, 30, 45, 60, 75, 105, 135, 165 minutes later. Method of measurement: Measurement with pressure gauge.</sec_outcome>
      <sec_outcome>Heart rate. Timepoint: Before the procedure, 5, 10, 15, 30, 45, 60, 75, 105, 135, 165 minutes later. Method of measurement: Measurement with non-invasive devices.</sec_outcome>
      <sec_outcome>Oxygen saturation. Timepoint: Before the procedure, 5, 10, 15, 30, 45, 60, 75, 105, 135, 165 minutes later. Method of measurement: Pulse Oximetry.</sec_outcome>
      <sec_outcome>Apgar score. Timepoint: At 1 and 5 minutes after birth. Method of measurement: Neonatal specialist examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-09-23</approval_date>
        <contact_name>Ethics committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>second floor, Deputy of Research and Technology, Saffarian Alley, 45 meters from Golshahr, Karaj. Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
